The RCT by Villar et al. in patients with Type II diabetes and chronic kidney disease divided the subjects into sub-normal Hb (110-129 g/L) and normal Hb (130-149 g/L) were given iron and/or erythropoietin stimulating agent (ESA) for correction of anemia for 6,12 18, 24 months and HbA1c did not vary significantly (P = 0.73) with correction of anemia [13]. This evidence concerns the gene GSTM1 and anemia (phenotype).